Zirconium Zr 89 Crefmirlimab Berdoxam
Non-Hodgkins Lymphoma
Hoffmann-La Rocheantibody_drug_conjugatePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Non-Hodgkins Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fnhlid1 Biovest International | Phase 3 | B |
Keyhole Limpet Hemocyanin Biovest International | Phase 3 | B |
Campth-1H SCRI Development Innovations, LLC | Phase 2 | B |
APG 115 Ascentage Pharma Group Inc. | Phase 2 | CCC |
Nemtabrutinib Merck Sharp & Dohme LLC | Phase 2 | CCC |
View all 18 →
Same molecule, other indications
Zirconium Zr 89 Crefmirlimab Berdoxam is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →